BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25253174)

  • 1. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.
    DeCensi A; Puntoni M; Gandini S; Guerrieri-Gonzaga A; Johansson HA; Cazzaniga M; Pruneri G; Serrano D; Schwab M; Hofmann U; Mora S; Aristarco V; Macis D; Bassi F; Luini A; Lazzeroni M; Bonanni B; Pollak MN
    Breast Cancer Res Treat; 2014 Nov; 148(1):81-90. PubMed ID: 25253174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
    Bonanni B; Puntoni M; Cazzaniga M; Pruneri G; Serrano D; Guerrieri-Gonzaga A; Gennari A; Trabacca MS; Galimberti V; Veronesi P; Johansson H; Aristarco V; Bassi F; Luini A; Lazzeroni M; Varricchio C; Viale G; Bruzzi P; Decensi A
    J Clin Oncol; 2012 Jul; 30(21):2593-600. PubMed ID: 22564993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.
    DeCensi A; Puntoni M; Guerrieri-Gonzaga A; Cazzaniga M; Serrano D; Lazzeroni M; Vingiani A; Gentilini O; Petrera M; Viale G; Cuzick J; Bonanni B; Pruneri G
    Cancer Prev Res (Phila); 2015 Oct; 8(10):888-94. PubMed ID: 26276754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.
    Martinez JA; Chalasani P; Thomson CA; Roe D; Altbach M; Galons JP; Stopeck A; Thompson PA; Villa-Guillen DE; Chow HH
    BMC Cancer; 2016 Jul; 16():500. PubMed ID: 27430256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of metformin on apoptosis in a breast cancer presurgical trial.
    Cazzaniga M; DeCensi A; Pruneri G; Puntoni M; Bottiglieri L; Varricchio C; Guerrieri-Gonzaga A; Gentilini OD; Pagani G; Dell'Orto P; Lazzeroni M; Serrano D; Viale G; Bonanni B
    Br J Cancer; 2013 Nov; 109(11):2792-7. PubMed ID: 24157825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials.
    Rahmani J; Manzari N; Thompson J; Gudi SK; Chhabra M; Naik G; Mousavi SM; Varkaneh HK; Clark C; Zhang Y
    Clin Transl Oncol; 2020 Jan; 22(1):37-49. PubMed ID: 31006835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.
    Niraula S; Dowling RJ; Ennis M; Chang MC; Done SJ; Hood N; Escallon J; Leong WL; McCready DR; Reedijk M; Stambolic V; Goodwin PJ
    Breast Cancer Res Treat; 2012 Oct; 135(3):821-30. PubMed ID: 22933030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin may protect nondiabetic breast cancer women from metastasis.
    El-Haggar SM; El-Shitany NA; Mostafa MF; El-Bassiouny NA
    Clin Exp Metastasis; 2016 Apr; 33(4):339-57. PubMed ID: 26902691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Metformin on Cancer Biomarkers in Non-Diabetic Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials.
    Farkhondeh T; Amirabadizadeh A; Aramjoo H; Llorens S; Roshanravan B; Saeedi F; Talebi M; Shakibaei M; Samarghandian S
    Curr Oncol; 2021 Apr; 28(2):1412-1423. PubMed ID: 33917520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it time to test metformin in breast cancer clinical trials?
    Cazzaniga M; Bonanni B; Guerrieri-Gonzaga A; Decensi A
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):701-5. PubMed ID: 19240238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin and insulin treatment of gestational diabetes: effects on inflammatory markers and IGF-binding protein-1 - secondary analysis of a randomized controlled trial.
    Huhtala MS; Tertti K; Juhila J; Sorsa T; Rönnemaa T
    BMC Pregnancy Childbirth; 2020 Jul; 20(1):401. PubMed ID: 32652973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial.
    Kitson SJ; Maskell Z; Sivalingam VN; Allen JL; Ali S; Burns S; Gilmour K; Latheef R; Slade RJ; Pemberton PW; Shaw J; Ryder WD; Kitchener HC; Crosbie EJ
    Clin Cancer Res; 2019 Apr; 25(8):2424-2432. PubMed ID: 30563932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study.
    Campagnoli C; Pasanisi P; Abbà C; Ambroggio S; Biglia N; Brucato T; Colombero R; Danese S; Donadio M; Venturelli E; Zito G; Berrino F
    Clin Breast Cancer; 2012 Jun; 12(3):175-82. PubMed ID: 22607767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials.
    Johansson H; Bellerba F; Macis D; Bertelsen BE; Guerrieri-Gonzaga A; Aristarco V; Viste K; Mellgren G; Di Cola G; Costantino J; Scalbert A; Sears DD; Gandini S; DeCensi A; Bonanni B
    Breast Cancer Res Treat; 2024 May; 205(1):49-59. PubMed ID: 38279016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F; Zamani MM; Heshmat R; Moini nia F
    J Obstet Gynaecol Res; 2013 Apr; 39(4):806-13. PubMed ID: 23279603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.
    Laskov I; Drudi L; Beauchamp MC; Yasmeen A; Ferenczy A; Pollak M; Gotlieb WH
    Gynecol Oncol; 2014 Sep; 134(3):607-14. PubMed ID: 24972190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
    Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study.
    Trolle B; Lauszus FF; Frystyk J; Flyvbjerg A
    Fertil Steril; 2010 Nov; 94(6):2234-8. PubMed ID: 20189560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes.
    Tan MH; Glazer NB; Johns D; Widel M; Gilmore KJ
    Curr Med Res Opin; 2004 May; 20(5):723-8. PubMed ID: 15140339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.